SCHEMBL17256196

SCHEMBL17256196

O=CCc1sc2ccccc2c1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.62
MCL1 Q07820 1/20 0.46
OGG1 O15527 1/20 0.45
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
KDM4E B2RXH2 4/20 0.40
GPR3 P46089 1/20 0.40
MAPT P10636 6/20 0.38
ALDH1A1 P00352 4/20 0.38
MEN1 O00255 3/20 0.38
GAA P10253 3/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
THRB P10828 2/20 0.38
LMNA P02545 1/20 0.38
ASIC3 Q9UHC3 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660322 0.83 LOXL2 (0.59) LOXL2MCL1OGG1HDAC1HDAC8
SCHEMBL2552331 0.79 PTGS2 (0.41) LOXL2MCL1OGG1HDAC1HDAC8
SCHEMBL6118386 0.79 ALDH1A1 (0.41) LOXL2GPR3MAPTALDH1A1MEN1
SCHEMBL7896583 0.77 LOXL2 (1.00) LOXL2MCL1OGG1HDAC1HDAC8
SCHEMBL6481714 0.77 LOXL2 (0.71) LOXL2MCL1OGG1HDAC1HDAC8
SCHEMBL2544178 0.76 PTPN1 (0.47) LOXL2GPR3L3MBTL1
SCHEMBL844195 0.76 LOXL2 (0.69) LOXL2MCL1OGG1HDAC1HDAC8
SCHEMBL15314583 0.76 LOXL2 (0.69) LOXL2MCL1OGG1HDAC1HDAC8
Hydrochloric Acid SCHEMBL20337908 0.76 LOXL2 (0.96) LOXL2MCL1OGG1HDAC1HDAC8
SCHEMBL658865 0.76 LOXL2 (0.69) LOXL2MCL1OGG1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394273-B2 Therapeutic prostaglandin receptor agonists ALLERGAN, INC. (US) 2016-07-19 US disclosed
US-20150329518-A1 THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS ALLERGAN, INC. 2015-11-19 US disclosed
WO-2015175984-A1 THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS ALLERGAN, INC. (US) 2015-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329518-A1 THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS PTGIR, PTGDR, PTGFR LOXL2 573/4885MCL1 4489/4885OGG1 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.